Home > Uwe Reuter, EAN 2020 – Characteristics of the HER-MES trial in episodic and chronic migraine
Headache Disorders

Uwe Reuter, EAN 2020 – Characteristics of the HER-MES trial in episodic and chronic migraine

Published Online: June 5th 2020

Uwe Reuter (Charité Universitätsmedizin Berlin, Germany) talks to us about the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine (ClinicalTrials.gov Identifier: NCT03828539).

Questions
1. What are the unmet needs in the treatment of episodic migraine? (
0:05)
2. Could you tell us a little about the objectives and design of the HER-MES study of erenumab vs topiramate? (
1:13)
3. What have been the findings of the study so far? (
3:10)
4. What has been the impact of antibodies targeting calcitonin gene-related peptide (CGRP) on the treatment landscape for episodic migraine? (
4:44)
5. How do you see the treatment of episodic migraine progressing in the next 5 years? (
6:50)

Speaker disclosure: Uwe Reuter reports having received honoraria for consulting and lectures within the past 3 years from Amgen, PharmAllergan, Eli Lilly, Lundbeck, Novartis Pharma, Hormosan Pharma, electroCore, Medscape, Novartis, StreaMedUp and Teva, he holds no stocks of pharmaceutical companies or medical device companies.

Support: Interview and filming supported by Touch Medical Media.

Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.

Related Videos In Headache Disorders
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar